Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas

Italiano, A., Cioffi, A., Penel, N., Levra, M. G., Delcambre, C., Kalbacher, E., Chevreau, C., Bertucci, F., Isambert, N., Blay, J. Y., Bui, B., Antonescu, C., D'Adamo, D. R., Maki, R. G., Keohan, M. L. (July 2012) Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer, 118 (13). pp. 3330-6. ISSN 1097-0142 (Electronic)0008-543X (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/22045619
DOI: 10.1002/cncr.26599

Abstract

BACKGROUND: Data regarding the role of anthracyclines and taxanes as first-line treatments of metastatic angiosarcoma are limited. METHODS: Records of 117 metastatic angiosarcoma patients who were treated with either doxorubicin or weekly paclitaxel were reviewed. RESULTS: Seventy-five patients (64%) were treated with weekly paclitaxel and 42 (36%) with single-agent doxorubicin. Patients in the weekly paclitaxel group were older and more frequently had angiosarcomas arising from the skin. In the doxorubicin group, 34 patients were evaluable for response: 2 (6%) had complete response, 8 (23.5%) had partial response, 10 (29.5%) had stable disease, and 14 (41%) had progressive disease. In the weekly paclitaxel group, 68 patients were evaluable for response: 9 (13%) had complete response, 27 (40%) had partial response, 20 (29.5%) had stable disease, and 12 (17.5%) had progressive disease. Objective responses to weekly paclitaxel were more frequent in cutaneous angiosarcomas, whereas tumor location did not impact response to doxorubicin. Median progression-free survival (PFS) was 4.9 months (95% confidence interval [95% CI], 3.9-6.0 months). Median overall survival (OS) was 8.5 months (95% CI, 6.4-10.7 months). On multivariate analysis, ECOG performance status (PS) was the sole independent factor associated with PFS and OS. CONCLUSIONS: First-line single-agent doxorubicin and weekly paclitaxel seem to have similar efficacy in metastatic angiosarcomas. Cutaneous angiosarcomas respond favorably to weekly paclitaxel. Best supportive care should be considered in patients with poor PS.

Item Type: Paper
Uncontrolled Keywords: Aged Antineoplastic Agents/*therapeutic use Disease-Free Survival Doxorubicin/*therapeutic use Female Follow-Up Studies Hemangiosarcoma/*drug therapy/mortality Humans Male Paclitaxel/*administration & dosage Prognosis Retrospective Studies Skin Neoplasms/*drug therapy/mortality
Subjects: diseases & disorders > cancer > cancer types > angiosarcoma
diseases & disorders > cancer > drugs and therapies
diseases & disorders > cancer > metastasis
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: 1 July 2012
Date Deposited: 20 Oct 2016 20:49
Last Modified: 20 Oct 2016 20:49
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33734

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving